IDYA - IDEAYA Biosciences, Inc.

33.03
-1.650   -4.995%

Share volume: 664,634
Last Updated: 03-05-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.31%

PREVIOUS CLOSE
CHG
CHG%
$34.68
-1.65
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
5%
Profitability 0%
Dept financing 2%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.03%
1 Month
2.67%
3 Months
-6.54%
6 Months
41.21%
1 Year
73.20%
2 Year
-28.75%
Key data
Stock price
$33.03
P/E Ratio 
0.00
DAY RANGE
$32.88 - $34.19
EPS 
-$1.28
52 WEEK RANGE
$13.45 - $39.28
52 WEEK CHANGE
$78.93
MARKET CAP 
3.031 B
YIELD 
N/A
SHARES OUTSTANDING 
87.814 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-05-2025
BETA 
1.24
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$915,827
AVERAGE 30 VOLUME 
$902,166
Company detail
CEO: Yujiro S. Hata
Region: US
Website: ideayabio.com
Employees: 80
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

IDEAYA Biosciences, Inc. focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions.

Recent news